XASX
MYX
Market cap155mUSD
Oct 09, Last price
2.66AUD
1D
-3.27%
1Q
-7.32%
Jan 2017
-90.11%
IPO
-65.00%
Name
Mayne Pharma Group Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Mayne Pharma Group Limited is an Australian-headquartered specialty pharmaceutical enterprise, engaged in the development, production, and marketing of both patented (branded) and generic drug formulations. Its commercial reach spans Australia, New Zealand, North America (covering the United States and Canada), Europe, and Asia. The company's operations are divided into four main segments: Metrics Contract Services, International, Branded Products, and Portfolio Products. Beyond its own product lines, Mayne Pharma offers sophisticated oral drug delivery technologies and comprehensive contract services—including pharmaceutical development, manufacturing, and analytical testing—to other businesses. Its strategic focus areas for specialty product distribution include dermatology, women's health, and infectious disease treatments. Originally established in 2005, the company operated under the name Halcygen Pharmaceuticals Limited before rebranding to Mayne Pharma Group Limited in November 2010. Its principal office is located in Salisbury South, Australia.
Key people
President - International Operations · since 2017
John Ross
President - Mayne Pharma USA · since 2017
Kate Rintoul
Executive Vice President, General Counsel · since 2015
Brant Schofield
Executive Vice President - Specialty Brands Division · since 2018
Ilana Stancovski
Chief Scientific Officer · since 2017
Andrew Herdman
Vice President, Group Human Resources
Scott Anthony Richards
Chief Executive Officer, Managing Director, Executive Director · since 2012
Peter Paltoglou
Chief Development Officer, Head of M&A · since 2016
Nick Freeman
Group Chief Financial Officer, Company Secretary · since 2017
Laura Loftus
Company Secretary · since 2020
Patrick J. Blake
Independent Non-Executive Director · since 2018
Independent Non-Executive Director · since 2018
Nancy Dolan
Independent Non-Executive Director · since 2016
Ian Frank Scholes
Independent Non-Executive Director · since 2007
Headquarters & legal address
1538 Main North Road,Salisbury South
Adelaide, SA 5106
AU
Adelaide, SA 5106
AU
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑06 | 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||